false
--12-31
Q1
0001973056
00-0000000
0001973056
2025-01-01
2025-03-31
0001973056
BOWN:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember
2025-01-01
2025-03-31
0001973056
BOWN:OrdinarySharesParValue0.0001PerShareMember
2025-01-01
2025-03-31
0001973056
BOWN:RightsEachEntitlingHolderToOnetenthOfOneOrdinaryShareUponCompletionOfCompanysInitialBusinessCombinationMember
2025-01-01
2025-03-31
0001973056
2025-07-08
0001973056
2025-03-31
0001973056
2024-12-31
0001973056
us-gaap:NonrelatedPartyMember
2025-03-31
0001973056
us-gaap:NonrelatedPartyMember
2024-12-31
0001973056
us-gaap:RelatedPartyMember
2025-03-31
0001973056
us-gaap:RelatedPartyMember
2024-12-31
0001973056
2024-01-01
2024-03-31
0001973056
BOWN:RedeemableOrdinarySharesMember
2025-01-01
2025-03-31
0001973056
BOWN:RedeemableOrdinarySharesMember
2024-01-01
2024-03-31
0001973056
BOWN:NonRedeemableOrdinarySharesMember
2025-01-01
2025-03-31
0001973056
BOWN:NonRedeemableOrdinarySharesMember
2024-01-01
2024-03-31
0001973056
us-gaap:CommonStockMember
2024-12-31
0001973056
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001973056
us-gaap:RetainedEarningsMember
2024-12-31
0001973056
us-gaap:CommonStockMember
2023-12-31
0001973056
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001973056
us-gaap:RetainedEarningsMember
2023-12-31
0001973056
2023-12-31
0001973056
us-gaap:CommonStockMember
2025-01-01
2025-03-31
0001973056
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-03-31
0001973056
us-gaap:RetainedEarningsMember
2025-01-01
2025-03-31
0001973056
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001973056
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-03-31
0001973056
us-gaap:RetainedEarningsMember
2024-01-01
2024-03-31
0001973056
us-gaap:CommonStockMember
2025-03-31
0001973056
us-gaap:AdditionalPaidInCapitalMember
2025-03-31
0001973056
us-gaap:RetainedEarningsMember
2025-03-31
0001973056
us-gaap:CommonStockMember
2024-03-31
0001973056
us-gaap:AdditionalPaidInCapitalMember
2024-03-31
0001973056
us-gaap:RetainedEarningsMember
2024-03-31
0001973056
2024-03-31
0001973056
us-gaap:NonrelatedPartyMember
2025-01-01
2025-03-31
0001973056
us-gaap:NonrelatedPartyMember
2024-01-01
2024-03-31
0001973056
us-gaap:RelatedPartyMember
2025-01-01
2025-03-31
0001973056
us-gaap:RelatedPartyMember
2024-01-01
2024-03-31
0001973056
us-gaap:IPOMember
2023-07-14
2023-07-14
0001973056
us-gaap:IPOMember
2023-07-14
0001973056
us-gaap:PrivatePlacementMember
2023-07-14
2023-07-14
0001973056
us-gaap:PrivatePlacementMember
2023-07-14
0001973056
us-gaap:OverAllotmentOptionMember
2023-07-17
2023-07-17
0001973056
us-gaap:OverAllotmentOptionMember
2023-07-18
2023-07-18
0001973056
us-gaap:OverAllotmentOptionMember
2023-07-18
0001973056
us-gaap:PrivatePlacementMember
2023-07-18
2023-07-18
0001973056
us-gaap:IPOMember
2023-07-18
2023-07-18
0001973056
us-gaap:IPOMember
2023-07-18
0001973056
2024-10-07
0001973056
BOWN:EarlyBirdCapitalMember
2024-10-07
0001973056
2025-01-10
2025-01-10
0001973056
2025-01-10
0001973056
2025-01-14
2025-01-14
0001973056
us-gaap:SubsequentEventMember
2025-04-14
2025-04-14
0001973056
us-gaap:SubsequentEventMember
2025-04-14
0001973056
BOWN:MergerSharesMember
BOWN:AgreementMember
2024-01-18
2024-01-18
0001973056
BOWN:EarnoutSharesMember
BOWN:AgreementMember
srt:MaximumMember
2024-01-18
2024-01-18
0001973056
BOWN:ForwardPurchaseAgreementMember
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
2025-01-13
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
2025-03-31
0001973056
BOWN:RedeemableSharesMember
2025-01-01
2025-03-31
0001973056
BOWN:NonRedeemableSharesMember
2025-01-01
2025-03-31
0001973056
BOWN:RedeemableSharesMember
2024-01-01
2024-03-31
0001973056
BOWN:NonRedeemableSharesMember
2024-01-01
2024-03-31
0001973056
us-gaap:IPOMember
2025-01-01
2025-03-31
0001973056
us-gaap:IPOMember
2025-03-31
0001973056
us-gaap:IPOMember
2024-12-31
0001973056
us-gaap:OverAllotmentOptionMember
2025-01-01
2025-03-31
0001973056
us-gaap:OverAllotmentOptionMember
2025-03-31
0001973056
us-gaap:OverAllotmentOptionMember
2023-12-31
0001973056
2024-01-01
2024-12-31
0001973056
us-gaap:OverAllotmentOptionMember
2024-01-01
2024-12-31
0001973056
us-gaap:OverAllotmentOptionMember
2023-07-14
2023-07-14
0001973056
BOWN:QianzhiMember
2025-01-01
2025-03-31
0001973056
BOWN:EBCFounderSharesMember
2024-10-14
0001973056
BOWN:EBCFounderSharesMember
2025-03-31
0001973056
BOWN:FounderSharesMember
2024-10-14
2024-10-14
0001973056
BOWN:FounderSharesMember
2024-10-14
0001973056
us-gaap:RelatedPartyMember
us-gaap:GeneralAndAdministrativeExpenseMember
2025-03-31
0001973056
us-gaap:RelatedPartyMember
BOWN:AccountingServicesExpenseMember
2025-03-31
0001973056
us-gaap:RelatedPartyMember
us-gaap:GeneralAndAdministrativeExpenseMember
2024-12-31
0001973056
us-gaap:RelatedPartyMember
BOWN:AccountingServicesExpenseMember
2024-12-31
0001973056
BOWN:AccountingServiceAgreementAndOtherMember
2025-01-01
2025-03-31
0001973056
BOWN:FounderSharesMember
2025-01-01
2025-03-31
0001973056
2024-10-14
2024-10-14
0001973056
us-gaap:FairValueInputsLevel3Member
us-gaap:MeasurementInputRiskFreeInterestRateMember
2024-10-14
0001973056
us-gaap:FairValueInputsLevel3Member
us-gaap:MeasurementInputPriceVolatilityMember
2024-10-14
0001973056
us-gaap:FairValueInputsLevel3Member
us-gaap:MeasurementInputExpectedDividendRateMember
2024-10-14
0001973056
us-gaap:FairValueInputsLevel3Member
BOWN:MeasurementInputProbabilityOfCompletionOfBusinessCombinationMember
2024-10-14
0001973056
us-gaap:RelatedPartyMember
BOWN:InitialAccountingServiceFeeMember
2025-03-31
0001973056
us-gaap:RelatedPartyMember
BOWN:InitialAccountingServiceFeeMember
2024-12-31
0001973056
us-gaap:RelatedPartyMember
BOWN:AccountingServiceFeeAndOthersMember
2025-03-31
0001973056
us-gaap:RelatedPartyMember
BOWN:AccountingServiceFeeAndOthersMember
2024-12-31
0001973056
us-gaap:RelatedPartyMember
BOWN:AdministrationFeeMember
2025-03-31
0001973056
us-gaap:RelatedPartyMember
BOWN:AdministrationFeeMember
2024-12-31
0001973056
BOWN:BusinessCombinationMarketingAgreementMember
2025-01-01
2025-03-31
0001973056
BOWN:BusinessCombinationMarketingAgreementMember
2025-03-31
0001973056
BOWN:ShenzhenQianzhiBioTechnologyCoLtdMember
2025-01-01
2025-03-31
0001973056
BOWN:ShenzhenQianzhiBioTechnologyCoLtdMember
2024-01-01
2024-03-31
0001973056
2025-01-13
2025-01-13
0001973056
2025-01-13
2025-03-31
0001973056
us-gaap:FairValueInputsLevel1Member
2025-03-31
0001973056
us-gaap:FairValueInputsLevel1Member
2024-12-31
0001973056
us-gaap:FairValueInputsLevel3Member
2025-03-31
0001973056
us-gaap:FairValueInputsLevel3Member
2024-12-31
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputSharePriceMember
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputSharePriceMember
2025-03-31
0001973056
BOWN:ForwardPurchaseAgreementMember
BOWN:MeasurementInputExpectedRedemptionPriceMember
us-gaap:ForwardContractsMember
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
BOWN:MeasurementInputExpectedRedemptionPriceMember
us-gaap:ForwardContractsMember
2025-03-31
0001973056
BOWN:ForwardPurchaseAgreementMember
BOWN:MeasurementInputTimeToExpirationMember
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
BOWN:MeasurementInputTimeToExpirationMember
2025-03-31
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2025-03-31
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputPriceVolatilityMember
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputPriceVolatilityMember
2025-03-31
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputExpectedDividendRateMember
2025-01-13
0001973056
BOWN:ForwardPurchaseAgreementMember
us-gaap:MeasurementInputExpectedDividendRateMember
2025-03-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
10-Q
☒ |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended March 31, 2025
OR
☐ |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the transition period from ___________ to __________
Commission
File Number: 001-41741
Bowen
Acquisition Corp
(Exact
name of registrant as specified in its charter)
Cayman
Islands |
|
N/A |
(State
or other jurisdiction |
|
(IRS
Employer |
of
incorporation or organization) |
|
Identification
Number) |
420
Lexington Ave, Suite 2446, New York, NY |
|
10170 |
(Address
of principal executive offices) |
|
(Zip
code) |
(203)
998-5540
(Issuer’s
telephone number including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Units,
each consisting of one ordinary share and one right |
|
BOWNU |
|
The
Nasdaq Stock Market LLC |
Ordinary
Shares, par value $0.0001 per share |
|
BOWN |
|
The
Nasdaq Stock Market LLC |
Rights,
each entitling the holder to one-tenth of one ordinary share upon the completion of the Company’s initial business combination
|
|
BOWNR |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act:
|
Large
accelerated filer ☐ |
Accelerated
filer ☐ |
|
|
Non-accelerated
filer ☒ |
Smaller
reporting company ☒ |
|
|
|
Emerging
growth company ☒ |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐
As
of July 8, 2025, the registrant had 3,010,973
ordinary shares, $0.0001
par value, outstanding.
INDEX
Part
I - Financial Information |
3 |
|
|
Item
1 – Financial Statements |
3 |
|
|
Consolidated
Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024 (Audited) |
3 |
|
|
Consolidated
Statements of Operations (Unaudited) |
4 |
|
|
Consolidated
Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited) |
5 |
|
|
Consolidated
Statements of Cash Flows (Unaudited) |
6 |
|
|
Notes
to Consolidated Unaudited Financial Statements |
7 |
|
|
Item
2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations |
19 |
|
|
Item
3 – Quantitative and Qualitative Disclosures About Market Risk |
21 |
|
|
Item
4 – Controls and Procedures |
21 |
|
|
Part
II - Other Information |
22 |
|
|
Item
2 – Unregistered Sales of Equity Securities and Use of Proceeds |
22 |
|
|
Item
5 – Other Information |
23 |
|
|
Item
6 – Exhibits |
23 |
|
|
Signatures |
24 |
Part
I - Financial Information
Item
1 – Financial Statements
BOWEN
ACQUISITION CORP
CONSOLIDATED
BALANCE SHEETS
| |
March 31, 2025 | |
December 31, 2024 |
| |
(Unaudited) | |
|
ASSETS | |
| | | |
| | |
Current Assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 29,806 | | |
$ | 103,774 | |
Other receivable (Note 5) | |
| 207,044 | | |
| 138,046 | |
Prepaid expenses | |
| 11,245 | | |
| 12,239 | |
Total Current Assets | |
| 248,095 | | |
| 254,059 | |
Investment held in Trust Account | |
| 9,372,109 | | |
| 75,794,241 | |
Total Assets | |
$ | 9,620,204 | | |
$ | 76,048,300 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accrued offering costs and expenses | |
$ | 401,970 | | |
$ | 309,004 | |
Accrued expenses - related party | |
| 136,613 | | |
| 101,285 | |
Accrued expenses | |
| 136,613 | | |
| 101,285 | |
| |
| | | |
| | |
Promissory note - related party (net of unamortized debt discount of $17,453 and $122,174, respectively) (Note 4) | |
| 482,547 | | |
| 377,826 | |
Promissory Note | |
| 190,000 | | |
| 190,000 | |
Payable to target company | |
| 75,000 | | |
| 75,000 | |
FPA liability (Note 5) | |
| 1,562,339 | | |
| — | |
Total Current Liabilities | |
| 2,848,469 | |
| | 1,053,115 |
| |
| | | |
| | |
Total Liabilities | |
| 2,848,469 | | |
| 1,053,115 | |
| |
| | | |
| | |
Commitments and contingencies (Note 5) | |
| - | | |
| - | |
Ordinary shares subject to possible redemption, 847,905 and 6,900,000 shares at redemption value of $11.05 and $10.98 per share as of March 31, 2025 and December 31, 2024, respectively | |
| 9,372,109 | | |
| 75,794,241 | |
| |
| | | |
| | |
Shareholders’ Deficit: | |
| | | |
| | |
Preferred shares, $0.0001 par value; 2,000,000 shares authorized; none issued and outstanding | |
| — | | |
| — | |
Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 2,266,500 shares issued and outstanding (excluding 847,905 and 6,900,000 shares subject to redemption on March 31, 2025 and December 31, 2024, respectively) | |
| 227 | | |
| 227 | |
Additional paid-in capital | |
| 238,679 | | |
| — | |
Accumulated deficit | |
| (2,839,280 | ) | |
| (799,283 | ) |
| |
| | | |
| | |
Total Shareholders’ Deficit | |
| (2,600,374 | ) | |
| (799,056 | ) |
Total Liabilities and Shareholders’ Deficit | |
$ | 9,620,204 | | |
$ | 76,048,300 | |
The
accompanying notes are an integral part of the unaudited consolidated financial statements.
BOWEN
ACQUISITION CORP
CONSOLIDATED
STATEMENTS OF OPERATIONS
(UNAUDITED)
| |
2025 | | |
2024 | |
| |
Three
Months Ended March 31, | |
| |
2025 | | |
2024 | |
Formation
and operating costs | |
$ | 134,736 | | |
$ | 137,130 | |
Loss
from operations | |
| (134,736 | ) | |
| (137,130 | ) |
| |
| | | |
| | |
Other
income (expense): | |
| | | |
| | |
Interest
earned on investments held in trust account | |
| 97,321 | | |
| 923,492 | |
Bank
interest income | |
| 478 | | |
| - | |
Interest
expenses | |
| (104,721 | ) | |
| - | |
Loss
on issuance of FPA liability | |
| (1,929,656 | ) | |
| - | |
Change
in fair value of FPA liability | |
| 367,317 | | |
| - | |
Financing expense | |
| (336,000 | ) | |
| | |
Total
other income (expense), net | |
| (1,905,261 | ) | |
| 923,492 | |
| |
| | | |
| | |
Net
(loss) income | |
$ | (2,039,997 | ) | |
$ | 786,362 | |
| |
| | | |
| | |
Basic
and diluted weighted average ordinary shares outstanding, redeemable ordinary shares | |
| 1,722,097 | | |
| 6,900,000 | |
Basic
and diluted net income (loss) per share, redeemable ordinary shares | |
$ | (0.48 | ) | |
$ | 0.12 | |
Basic
and diluted weighted average ordinary shares outstanding, non-redeemable ordinary shares | |
| 2,266,500 | | |
| 2,266,500 | |
Basic
and diluted net loss per share, non-redeemable ordinary shares | |
$ | (0.54 | ) | |
$ | (0.01 | ) |
The
accompanying notes are an integral part of the unaudited consolidated financial statements.
BOWEN
ACQUISITION CORP
CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
(UNAUDITED)
FOR
THREE MONTHS ENDED MARCH 31, 2025
| |
Shares | | |
Amount | | |
Capital | | |
Deficit) | | |
(Deficit) | |
| |
Ordinary
Shares | | |
Additional
Paid-in | | |
Accumulated
| | |
Total
Shareholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficits | | |
Deficit | |
Balance
as of January 1, 2025 | |
| 2,266,500 | | |
$ | 227 | | |
$ | - | | |
$ | (799,283 | ) | |
$ | (799,056 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Financing expense allocated to APIC | |
| - | | |
| - | | |
| 336,000 | | |
| - | | |
| 336,000 | |
Subsequent
measurement of Common stock subject to possible redemption (interest earned on trust account) | |
| - | | |
| - | | |
| (97,321 | ) | |
| - | | |
| (97,321 | ) |
Net
loss | |
| - | | |
| - | | |
| - | | |
| (2,039,997 | ) | |
| (2,039,997 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance
as of March 31, 2025 | |
| 2,266,500 | | |
$ | 227 | | |
$ | 238,679 | | |
$ | (2,839,280 | ) | |
$ | (2,600,374 | ) |
FOR
THREE MONTHS ENDED MARCH 31, 2024
| |
Ordinary
Shares | | |
Additional Paid-in | | |
Retained | | |
Total Shareholders’
| |
| |
Shares | | |
Amount | | |
Capital | | |
Earnings | | |
Equity | |
Balance
as of January 1, 2024 | |
| 2,266,500 | | |
$ | 227 | | |
$ | - | | |
$ | 402,307 | | |
$ | 402,534 | |
Balance | |
| 2,266,500 | | |
$ | 227 | | |
$ | - | | |
$ | 402,307 | | |
$ | 402,534 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Subsequent
measurement of Common stock subject to possible redemption (interest earned on trust account) | |
| - | | |
| - | | |
| - | | |
| (923,492 | ) | |
| (923,492 | ) |
Net
income | |
| - | | |
| - | | |
| - | | |
$ | 786,362 | | |
| 786,362 | |
Net
income (loss) | |
| - | | |
| - | | |
| - | | |
$ | 786,362 | | |
| 786,362 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance
as of March 31, 2024 | |
| 2,266,500 | | |
$ | 227 | | |
$ | - | | |
$ | 265,177 | | |
$ | 265,404 | |
Balance | |
| 2,266,500 | | |
$ | 227 | | |
$ | - | | |
$ | 265,177 | | |
$ | 265,404 | |
The
accompanying notes are an integral part of the unaudited consolidated financial statements.
BOWEN
ACQUISITION CORP
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
2025 | | |
2024 | |
| |
For
Three Months Ended March 31, | |
| |
2025 | | |
2024 | |
Cash
flows from operating activities: | |
| | | |
| | |
Net
income (loss) | |
$ | (2,039,997 | ) | |
$ | 786,362 | |
Adjustments
to reconcile net income (loss) to net cash used in operating activities: | |
| | | |
| | |
Income
earned on investment held in Trust Account | |
| (97,321 | ) | |
| (923,492 | ) |
Amortized
interest expense from debt discount | |
| 104,721 | | |
| - | |
Loss
on issuance of FPA liability | |
| 1,929,656 | | |
| - | |
Change
in fair value of FPA liability | |
| (367,317 | ) | |
| - | |
Financing expense | |
| 336,000 | | |
| - | |
Changes
in current assets and liabilities: | |
| | | |
| | |
Accrued
offering costs and expenses | |
| 21,190 | | |
| 44,255 | |
Accrued
expenses - related party | |
| 31,995 | | |
| (15,250 | ) |
Accrued
expenses | |
| 31,995 | | |
| (15,250 | ) |
Prepaid
Expenses | |
| 7,105 | | |
| 17,171 | |
Net
cash used in operating activities | |
| (73,968 | ) | |
| (90,954 | ) |
| |
| | | |
| | |
Cash
flows from investing activities: | |
| | | |
| | |
Cash
withdrawn from trust account in connection with redemption | |
| 66,519,453 | | |
| - | |
Net
cash provided by investing activities | |
| 66,519,453 | | |
| - | |
| |
| | | |
| | |
Cash
flows from financing activities: | |
| | | |
| | |
Payment of public shareholders’ redemption | |
| (66,519,453 | ) | |
| - | |
Net
cash used in financing activities | |
| (66,519,453 | ) | |
| - | |
| |
| | | |
| | |
Net
change in cash | |
| (73,968 | ) | |
| (90,954 | ) |
Cash
at beginning of period | |
| 103,774 | | |
| 426,913 | |
Cash
at the end of period | |
$ | 29,806 | | |
$ | 335,959 | |
| |
| | | |
| | |
Supplemental
disclosure of noncash financing activities | |
| | | |
| | |
| |
| | | |
| | |
Subsequent
measurement of ordinary shares subject to possible redemption (income earned on trust account) | |
$ | 97,321 | | |
| 923,492 | |
The
accompanying notes are an integral part of the unaudited consolidated financial statements.
BOWEN
ACQUISITION CORP
UNAUDITED
Notes to the consolidated financial statements
NOTE
1 — ORGANIZATION AND BUSINESS OPERATIONS
Organizational
and General
Bowen
Acquisition Corp (the “Company”) was incorporated in the Cayman Islands on February 17, 2023. The Company was formed for
the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination
with one or more businesses (the “Business Combination”).The Company is not limited to a particular industry or sector for
purposes of consummating a Business Combination.
The
Company’s sponsors are Createcharm Holdings Ltd., a British Virgin Islands company, and Bowen Holding LP, a Delaware limited partnership
(the “Sponsors”). As of March 31, 2025, the Company had not commenced any operations. All activities for the period from
February 17, 2023 (inception) through March 31, 2025 relate to the Company’s formation, the initial public offering (“IPO”)
and initial business combination, which is described below. The Company will not generate any operating revenues until after the completion
of an initial Business Combination, at the earliest. The Company is generating non-operating income in the form of interest income from
the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.
The
registration statement for the Company’s IPO (the “Registration Statement”) was declared effective on July 11, 2023.
On July 14, 2023, the Company consummated the IPO of 6,000,000 of its units (“Public Units”). Each Public Unit consists of
one ordinary share, $0.0001 par value (“Ordinary Shares”), of the Company and one right (“Rights”), each Right
entitling the holder thereof to receive one-tenth of one ordinary share upon the completion of the Company’s initial business combination.
The Public Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $60,000,000.
Simultaneously
with the consummation of the IPO, the Company consummated the private placement (“Private Placement”) of 330,000 units (“Private
Placement Units”) at a price of $10.00 per Private Placement Unit, generating total proceeds of $3,300,000. The Private Placement
Units were purchased by Createcharm Holdings Ltd, one of the Company’s sponsors, and EarlyBirdCapital, Inc. (“EBC”),
the representative of the underwriters in the IPO. The Private Placement Units are identical to the Units included in the Public Units
sold in the IPO. The purchasers of the Private Placement Units have agreed not to transfer, assign or sell any of the Private Placement
Units or Ordinary Shares or Rights underlying the Private Placement Units (except to certain transferees) until after the completion
of the Company’s initial Business Combination.
On
July 17, 2023, the underwriters exercised their over-allotment option in full to purchase an additional 900,000 Units. As a result, on
July 18, 2023, the Company sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds of $9,000,000. In connection
with this sale, Createcharm Holdings Ltd. and EBC also purchased an additional 31,500 Private Placement Units from the Company.
As
of July 18, 2023, transaction costs amounted to $3,318,898 consisting of $1,725,000 of cash underwriting fees and $1,593,898 of other
offering costs. These costs were charged to additional paid-in capital or accumulated deficit to the extent additional paid-in capital
is fully depleted upon completion of the IPO.
The
Company will have until 18 months from the closing of the IPO to consummate a Business Combination (the “Combination Period”).
However, if the Company has not completed a Business Combination within the Combination Period and shareholders have not otherwise amended
the Amended and Restated Memorandum and Articles of Association to extend this period, the Company will (i) cease all operations except
for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of
the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including
interest earned and not previously released to us to pay the Company’s taxes, if any (less certain amount of interest to pay dissolution
expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights
of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly
as reasonably possible following such redemption, subject to the approval of the Company’s remaining Public Shareholders and its
Board of Directors, liquidate and dissolve, subject to the Company’s obligations under Cayman Islands law to provide for claims
of creditors and the requirements of other applicable law.
On
November 20, 2023, a wholly-owned subsidiary of the Company, Bowen Merger Sub (“Merger Sub”) was formed for the purpose of
entering into a business combination agreement. See “Proposed Business Combination” below.
Effective
as of October 7, 2024, the Company notified the trustee of the Trust Account that it was extending the time to consummate an initial
Business Combination from October 14, 2024 to January 14, 2025. Effective as of October 14, 2024, Shenzhen Qianzhi (as defined below)
and EBC, two designees of the Sponsors, loaned the Company an aggregate of $690,000, which funds were deposited into the Trust Account
for such extension. The loans are evidenced by promissory notes (the “Notes”) issued by the Company to the designees. The
Notes bear no interest and are repayable in full upon consummation of a Business Combination. In connection with the loans, one of the
Sponsors transferred 30,000 of its Founder Shares to EBC.
The
Company had called an extraordinary general meeting (the “Extension Meeting”) for January 10, 2025 to approve, by special
resolution and pursuant to the terms of the Company’s amended and restated memorandum and articles of association, as amended (the
“Articles”), an amendment to the Articles to allow the board of directors of the Company (the “Board”) to extend
the date by which the Company must consummate a merger, share exchange, asset acquisition, share purchase, reorganization or similar
business combination with one or more businesses (a “business combination”), by up to three one-month increments, from January
14, 2025 to as late as April 14, 2025, unless the closing of a business combination shall have occurred prior thereto or such earlier
date as shall be determined by the Board in its sole discretion. In connection with the meeting, an aggregate of 6,052,095 Public Shares
were redeemed at a price of approximately $10.99 per share. Following the redemptions, the Company has 847,905 Public Shares, and approximately
$9,319,446 remaining in Trust Account.
On
January 14, 2025, the Company held another extraordinary general meeting to approve the business combination with Qianzhi (as
defined below). At the meeting, all proposals were approved by shareholders. An aggregate of 137,936
Public Shares requested redemption in connection with such vote which will be redeemed on the business combination consummation date.
On
April 14, 2025, the Company held an extraordinary general meeting to approve a proposal to extend the time the Company had to consummate
its initial Business Combination to up to July 14, 2025. In connection with the meeting, an aggregate of 103,432 Public Shares were redeemed
at a price of approximately $11.07 per share. Following the redemptions, the Company has 744,473 Public Shares, and approximately $8,241,047
remaining in Trust Account.
Proposed
Business Combination
On
January 18, 2024, the Company entered into an Agreement and Plan of Reorganization (the “Agreement”) with (i) Bowen Merger
Sub, a Cayman Islands exempted company and a wholly owned subsidiary of the Company (“Merger Sub”), (ii) Shenzhen Qianzhi
BioTechnology Co. Ltd., a company incorporated in the People’s Republic of China and a wholly owned subsidiary of NewCo (as defined
below) (“Shenzhen Qianzhi”or “Qianzhi”), and (iii) Qianzhi Group Holding (Cayman) Limited, a newly formed Cayman
Islands company (“NewCo,” and collectively with the Company, Merger Sub and Shenzhen Qianzhi, the “Parties”,
each a “Party”).
Pursuant
to the Agreement, at the closing of the business combination, Merger Sub will merge with and into NewCo (the “Merger”),
with NewCo being the surviving company of the Merger (“Surviving Company”) and becoming a wholly owned subsidiary
of the Company. In the Merger, the holders (the “NewCo Shareholders”) of the ordinary shares of NewCo (“NewCo Ordinary
Shares”) will receive ordinary shares of the Company (“Parent Ordinary Shares”).
Pursuant
to the Agreement, at the effective time of the Merger (the “Effective Time”), all of NewCo Ordinary Shares issued and outstanding
immediately prior to the Effective Time will be automatically converted into the right to receive an aggregate of (a) 7,246,377 Parent
Ordinary Shares (the “Merger Shares”), and (b) the right to receive earnout consideration of up to an aggregate of 1,400,000
Parent Ordinary Shares (the “Earnout Shares”).
The
Company’s Registration Statement on Form S-4 (“S-4”) was declared effective on December 18, 2024. As of the filing
date, the business combination remained pending, awaiting required regulatory approvals.
On
January 13, 2025, the Company entered into Prepaid Forward Purchase Agreement (the “FPA”) by and among the Company, NewCo,
and the funds, accounts and/other investment vehicles managed by Harraden Circle Investments, LLC signatory thereto (collectively, the
“Purchaser”). In accordance with the FPA and subject to the terms and conditions set forth therein, the Purchaser shall purchase
from holders of Public Shares, par value $0.0001 per share, of the Company (“Company Ordinary Share”) that have elected
to redeem their Company Ordinary Shares in connection with the contemplated business combination (“Business Combination”)
between the Company, NewCo and Qianzhi, up to the lesser of (a) 550,000 Company Ordinary Shares and (b) such number of Company Ordinary
Shares as shall, following the Business Combination between the Company, NewCo and Qianzhi, not to exceed 9.9% of the total number of
Company Ordinary Shares to be outstanding (such shares to be purchased, the “Forward Purchase Shares”) from public shareholders
for a price no greater than the redemption price (the “Redemption Price”) per share to be paid to redeeming public shareholders
of the Company. Upon the Business Combination closing, 50,000 Purchased Shares shall be deemed to be “Commitment Shares”
and the remaining Forward Purchased Shares shall be deemed to be “Prepaid Forward Purchase Shares”. No later than the earlier
of (a) one business day after the Business Combination closing and (b) the date any assets from the Company’s trust account are
disbursed in connection with the Business Combination, the Company and NewCo shall cause Purchaser to be paid directly, out of the funds
held in the Company’s trust account, a cash amount (the “Prepayment Amount”) equal to the number of Forward Purchased
Shares multiplied by the Redemption Price. Upon the subsequent sale of the Prepaid Forward Purchase Shares by the Purchaser, the Purchaser
will remit the Reference Price (as defined below) per share to the Company. On the date that is twelve months after the closing of the
Business Combination (the “Maturity Date”), any Prepaid Forward Purchase Shares not sold by the Purchaser will be returned
by the Purchaser to the Company and any remaining amounts in respect of the Prepaid Forward Purchase Shares will be retained by Purchaser.
Prior to the Maturity Date, the Purchaser may sell Commitment Shares at any price in Purchaser’s sole discretion. The Purchaser
has agreed that until the Maturity Date, the Prepaid Forward Purchase Shares may not be sold for a price less than the Reference Price.
The “Reference Price” will initially equal the Redemption Price and may, at the Company’s option, be reduced (but never
increased) at any time to the lowest daily volume weighted average price of the Company Ordinary Shares for the preceding 10 trading
days.
Going
Concern Consideration
As
of March 31, 2025, the Company had cash and cash equivalent of $29,806 and a working capital deficit of $2,600,374. The Company has incurred
and expects to continue to incur significant professional costs to remain as a public traded company and to incur transaction costs in
pursuit of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with
Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue
as a Going Concern,” management believes that these conditions raise substantial doubt about the Company’s ability to continue
as a going concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period and such period
is not extended, there will be a liquidation and subsequent dissolution. As a result, management has determined that such additional
condition also raises substantial doubt about the Company’s ability to continue as a going concern. Management expects to obtain
additional funds from related parties to provide the additional working capital necessary to carry out its objective to consummate a
business combination. The consolidated financial statements does not include any adjustments that might result from the outcome of the
uncertainty.
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation and Principles of Consolidation
The
accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to
Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements
prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial
reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position,
results of operations, or cash flows. In the opinion of management, the unaudited financial statements reflect all adjustments, which
include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The
interim results for the period ended March 31, 2025 are not necessarily indicative of the results that may be expected through December
31, 2025. All intercompany accounts and transactions are eliminated upon consolidation. The information included in this Form 10-Q should
be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2024,
filed with the Securities and Exchange Commission on April 15, 2025.
Emerging
Growth Company
The
Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities
Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation
requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved.
Further,
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of
such extended transition period which means that when a standard is issued or revised and it has different application dates for public
or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies
adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which
is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult
or impossible because of the potential differences in accounting standards used.
Use
of Estimates
The
preparation of the consolidated financial statement in conformity with US GAAP requires the Company’s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statement.
Making
estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of
a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating
its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ
significantly from those estimates.
Cash
and cash equivalents
The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.
The Company had a cash and cash equivalents balance of $29,806 and $103,774 as of March 31, 2025 and December 31, 2024, respectively.
Investments
Held in Trust Account
The
Company’s portfolio of investments held in the Trust Account is comprised of investments only in U.S. government securities
with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company
Act which invest only in direct U.S. government treasury obligations. The Company’s investments held in the Trust Account are
classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting
period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest
earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair value of
investments held in the Trust Account is determined using available market information. As of March 31, 2025 and December 31, 2024,
the Trust Account had balance of $9,372,109
and $75,794,241,
respectively. The interest and dividend income earned from the Trust Account totaled $97,321
and $923,492
for three months ended March 31, 2025 and 2024, respectively, which were fully reinvested into the Trust Account as earned and
unrealized gain on investments and therefore presented as an adjustment to the operating activities in the Consolidated Statements
of Cash Flows.
Offering
Costs
Offering
costs consist of legal and other costs (including underwriting discounts and commissions) incurred through the balance sheet date that
are directly related to the IPO and that were charged to shareholders’ equity upon the completion of the IPO on July 14, 2023.
Interest
Expenses
Interest
expense in 2024 and 2025 are primarily from the amortization of the debt discount in connection with the promissory note issued by the
Company to related party. See Note 4 - Related Parties
for more information.
Amortization
of Debt Discount
The
Company’s promissory note issued with related party is recorded net of debt discount which comprised issuance costs, and the discount
initially recognized for the fair value of the shares transferred. The portion of the debt issuance costs allocated to the promissory
note, is being amortized over the terms, which is upon consummation of the Business Combination. The amortization of debt issuance costs
and discount is included in interest expense within the accompanying consolidated statements of operations.
FPA
Liability
The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives,
pursuant to ASC 480, “Distinguishing Liabilities from Equity” and ASC 815-40, “Derivatives and Hedging—Contracts
in Entity’s Own Equity” (“ASC 815-40”). The classification of derivative instruments, including whether such
instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
The
forward purchase option in the FPA of the Company meets the definition of an obligation to repurchase shares by transferring
assets arrangement under ASC 480-10, therefore, the forward purchase option is required to be classified as a liability at fair
value. Subsequently, changes in fair value are reported in earnings in statements of operations.
Financing Expenses
The Company accounts for its share-based
compensation in accordance with ASC 718, Compensation – Stock Compensation. Share-based compensation cost is measured
at the grant date, based on the estimated fair value of the award, and is recognized as expense over the requisite service period.
The 50,000 Commitment Shares in the FPA is an equity consideration transferred to a non-employee for financing services and
therefore falls within the scope of ASC 718-10. The fair value of the financing expenses shall be measured based on the observable
market price.
Income
Taxes
The
Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred
tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial
statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.
ASC
740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax
positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely
than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to
unrecognized tax benefits as income tax expense. There were no
unrecognized tax benefits and no
amounts accrued for interest and penalties as of March 31, 2025 and December 31, 2024. The Company is currently not aware of any
issues under review that could result in significant payments, accruals, or material deviation from its position.
There
is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations,
income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial
statements.
Net
Income (Loss) per Ordinary Share
The
Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The statements of operations include
a presentation of income (loss) per redeemable share and income (loss) per non-redeemable share following the two-class method of income
per share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company
first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed
income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss)
ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement
of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public
shareholders. As of March 31, 2025 and 2024, the Company did not have any dilutive securities and other contracts that could, potentially,
be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income (loss) per
share is the same as basic income (loss) per share for the period presented.
The
net income (loss) per share presented in the statements of operations is based on the following:
SCHEDULE
OF NET INCOME (LOSS) PER SHARE PRESENTED STATEMENTS OF OPERATIONS
| |
2025 | | |
2024 | |
| |
For
Three Months Ended March 31, | |
| |
2025 | | |
2024 | |
Net
income (loss) | |
$ | (2,039,997 | ) | |
$ | 786,362 | |
Interest
earned on investment held in Trust Account | |
| (97,321 | ) | |
| (923,492 | ) |
Net
loss including accretion of equity into redemption value | |
$ | (2,137,318 | ) | |
$ | (137,130 | ) |
SCHEDULE
OF EARNINGS PER SHARE BASIC AND DILUTED
| |
Redeemable | | |
Non-
Redeemable | | |
Redeemable | | |
Non-
Redeemable | |
| |
For
Three Months Ended March 31, | |
| |
2025 | |
2024 | |
| |
Redeemable | | |
Non-
Redeemable | | |
Redeemable | | |
Non-
Redeemable | |
Particulars | |
Shares | | |
Shares | | |
Shares | | |
Shares | |
Basic
and diluted net income (loss) per share: | |
| | | |
| | | |
| | | |
| | |
Weighted-average
shares outstanding | |
| 1,722,097 | | |
| 2,266,500 | | |
| 6,900,000 | | |
| 2,266,500 | |
Ownership
percentage | |
| 43 | % | |
| 57 | % | |
| 75 | % | |
| 25 | % |
Numerators: | |
| | | |
| | | |
| | | |
| | |
Allocating net (loss) income including accretion of temporary equity | |
| (922,798 | ) | |
| (1,214,520 | ) | |
| (103,223 | ) | |
| (33,907 | ) |
Interest
earned on Trust Account | |
| 97,321 | | |
| - | | |
| 923,492 | | |
| - | |
Allocation
of net income (loss) | |
$ | (825,477 | ) | |
| (1,214,520 | ) | |
$ | 820,269 | | |
$ | (33,907 | ) |
| |
| | | |
| | | |
| | | |
| | |
Denominators: | |
| | | |
| | | |
| | | |
| | |
Weighted-average
shares outstanding | |
| 1,722,097 | | |
| 2,266,500 | | |
| 6,900,000 | | |
| 2,266,500 | |
Basic
and diluted net income/(loss) per share | |
$ | (0.48 | ) | |
$ | (0.54
| ) | |
$ | 0.12 | | |
$ | (0.01 | ) |
Concentration
of Credit Risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts
and management believes the Company is not exposed to significant risks on such accounts.
Fair
Value of Financial Instruments
The forward purchase option in the FPA of the Company meets the definition
of an obligation to repurchase shares by transferring assets arrangement under ASC 480 and therefore qualify as financial instruments
under ASC 820 “Fair Value Measurement.” The Company’s FPA liability is
considered to be Level 3 financial instruments measured at fair value on a recurring basis. See Note 7 for details. The fair value of
the Company’s other assets and liabilities, which qualify as financial instruments under ASC 820, approximates the carrying amounts
represented in the balance sheet, primarily due to their short-term nature.
Ordinary
Shares Subject to Possible Redemption
The
Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification
(“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if
any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary
shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence
of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares
are classified as shareholders’ equity. The Company’s ordinary shares features certain redemption rights that are considered
to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject
to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the
Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying
value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the
carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated deficit.
At
March 31, 2025, the ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:
SCHEDULE
OF ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION REFLECTED IN THE BALANCE SHEET
Public
offering proceeds | |
$ | 60,000,000 | |
Less: | |
| | |
Proceeds
allocated to Public Rights | |
| (3,272,724 | ) |
Allocation
of offering costs related to redeemable shares | |
| (2,925,140 | ) |
Plus: | |
| | |
Accretion
of carrying value to redemption value | |
| 6,797,864 | |
Ordinary
shares subject to possible redemption | |
| 60,600,000 | |
| |
| | |
Over-allotment | |
| | |
Plus: | |
| | |
Over-allotment
proceeds | |
| 9,000,000 | |
Less: | |
| | |
Proceeds
allocated to Public Rights | |
| (490,909 | ) |
Allocation
of offering costs related to redeemable shares | |
| (212,727 | ) |
Plus: | |
| | |
Accretion
of carrying value to redemption value | |
| 793,636 | |
Subsequent
measurement of ordinary shares subject to possible redemption (income earned on trust account) | |
| 1,729,358 | |
Ordinary
shares subject to possible redemption, December 31, 2023 | |
$ | 71,419,358 | |
Plus: | |
| | |
Subsequent
measurement of ordinary shares subject to possible redemption (income earned on trust account) | |
| 3,684,883 | |
Subsequent
measurement of ordinary shares subject to possible redemption (extension deposit) | |
| 690,000 | |
Ordinary
shares subject to possible redemption, December 31, 2024 | |
$ | 75,794,241 | |
Subsequent
measurement of ordinary shares subject to possible redemption (income earned on trust account) | |
| 97,321 | |
Subsequent
measurement of ordinary shares subject to possible redemption (redemption) | |
| (66,519,453 | ) |
Ordinary
shares subject to possible redemption, March 31, 2025 | |
$ | 9,372,109 | |
Recent
Accounting Standards
Management
does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect
on the Company’s consolidated financial statements.
NOTE
3 — INITIAL PUBLIC OFFERING
On
July 14, 2023, the Company sold 6,000,000 Units at a price of $10.00 per Unit. Each Unit consists of one ordinary share and one right
to receive one-tenth (1/10) of one ordinary share upon the consummation of the Company’s initial Business Combination. Ten Public
Rights will entitle the holder to one ordinary share (see Note 6). The Company will not issue fractional shares and only whole shares
will trade, so unless a holder purchased units in multiples of tens, such holder will not be able to receive or trade the fractional
shares underlying the rights. The Company also granted the underwriters a 45-day option to purchase up to an additional 900,000 units
to cover over-allotments. The over-allotment was subsequently fully exercised on July 17, 2023. See Note 1 for further details.
The
Company incurred $75,000
Nasdaq delayed entry fee during the IPO in 2023 and this balance was subsequently paid by Qianzhi which is the target company. As of
March 31, 2025 and December 31, 2024, this balance is recorded as “Payable to target” on the consolidated balance sheet.
NOTE
4 — RELATED PARTIES
Promissory Note – Related
Party
On October 14, 2024, EBC loaned the Company $500,000 which funds were deposited into the Trust Account for the
extension. The loan is evidenced by promissory note issued by the Company (“Extension Note”). The Extension Note bears no
interest and is repayable in full upon consummation of a Business Combination. As of March
31, 2025, $500,000 was outstanding.
In connection with the loan, one of the Sponsors transferred of its Founder Shares to EBC. The value
of the shares transferred is reflected as debt discount and fully amortized as interest expense over the life of the loan per ASC 835.
See below for more details.
Founder
Shares
On
October 14, 2024, one of the Sponsors transferred
of its Founder Shares to EBC in connection with $500,000
loan for the extension.
The
Company estimated the fair value of the Founder Shares to be approximately $209,442 or $6.98 per share using the Black-Scholes option
pricing model. The fair value of the Founder Shares was estimated at October 14, 2024. The Company
used the following assumptions to estimate the fair value of Founder Shares using Level 3 fair value measurements inputs at the measurement
date:
SCHEDULE
OF ASSUMPTIONS TO ESTIMATE FAIR VALUE
Time
to expiration | |
| 1.0 | |
Risk-free
rate | |
| 4.2 | % |
Volatility | |
| 5.0 | % |
Dividend
yield | |
| 0.0 | % |
Probability
of completion of business combination | |
| 65.0 | % |
Based
on the fair value of the Founder Shares, the Company recorded a debt discount of $209,442,
which is amortized as interest expense over the loan period. The loan period extends until the consummation of the Business
Combination, estimated to occur on April 15, 2025. As of the filing date, the Business Combination has not been consummated. Since
the loan period change is immaterial and the Business Combination will be consummated this year, no adjustment to the amortization
is considered necessary. For three months ended March 31, 2025 and for the year ended December 31, 2024, the Company has recorded an
interest expense of $104,721
and $87,267, respectively. The note is presented net of an unamortized debt discount of $17,453, resulting in a carrying amount of $482,547
as of March 31, 2025.
Due
to Related Party
The
Sponsors paid certain formation, operating or offering costs on behalf of the Company. These amounts were due on demand and non-interest
bearing.
As
of March 31, 2025, the total accrued expenses due to related parties was $136,613, which includes $120,000 payable for administration
fee and $16,613 payable for accounting related and other service fee.
As
of December 31, 2024, the total accrued expenses due to related parties was $101,285, which includes $90,000 payable for administration
fee and $11,285 payable for accounting related and other service fee.
Accounting
Service Agreement and Others
The
Company has engaged TenX Global Capital, a related party of the Company, to assist in initial accounting preparation, preparing quarterly
and annual financial statements commencing following the consummation of the IPO. The Company has agreed to pay for these services at
a fixed quarterly rate of $5,250 each quarter. TenX Global Capital also provides other services following the consummation of the IPO.
Administration
Fee
Commencing
on the effectiveness of the Registration Statement on July 11, 2023, an affiliate of the Sponsors will be allowed to charge the Company
an allocable share of its overhead, up to $ per month, until to the close of the Business Combination, to compensate it for the
Company’s use of its office, utilities and personnel.
The
following table presents details about the expenses incurred for three months ended March 31, 2025 and 2024, respectively, and payable
as of March 31, 2025 and December 31, 2024, respectively:
SCHEDULE
OF EXPENSES INCURRED AND PAYABLES
| |
| | |
| | |
| | |
| |
Nature | |
Operating
Costs For
the three months ended | | |
Payable
Balance as of | |
| |
March
31, 2025 | | |
March
31, 2024 | | |
March
31, 2025 | | |
December
31, 2024 | |
Initial
accounting service fee | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Accounting
service fee and others | |
| 5,328 | | |
| 5,441 | | |
| 16,613 | | |
| 11,285 | |
Administration
fee | |
| 30,000 | | |
| 30,000 | | |
| 120,000 | | |
| 90,000 | |
Total | |
$ | 35,328 | | |
$ | 35,441 | | |
$ | 136,613 | | |
$ | 101,285 | |
NOTE
5 — COMMITMENTS AND CONTINGENCIES
Registration
Rights
The
holders of the Founder Shares, EBC founder shares, Private Placement Units have certain
“piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination
and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the
registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration
statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear
the expenses incurred in connection with the filing of any such registration statements.
Business
Combination Marketing Agreement
The
Company has engaged EBC as an advisor in connection with its Business Combination to assist in holding meetings with the Company stockholders
to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors
that are interested in purchasing its securities in connection with its initial Business Combination and assist with press releases and
public filings in connection with the Business Combination. The Company will pay EBC a service fee for such services upon the consummation
of its initial Business Combination in an amount of $2,415,000,
equal to 3.5%
of the gross proceeds of the IPO. In addition, the Company will pay EBC a service fee in an amount equal to 1.0%
of the total consideration payable in the initial Business Combination if it introduces the Company to the target business with whom
it completes an initial Business Combination and the amount will be payable in cash and is due at the closing date of the initial Business
Combination. As of the filing date, no such service has been provided by EBC.
Business
Combination Transaction Cost
The
Company has engaged several service providers including legal and valuation services, specifically for business combination between
the Company and Shenzhen Qianzhi BioTechnology Co. Ltd. (“Qianzhi”). Per the agreed terms, Qianzhi agreed to be
responsible for all expenses incurred by the Company in connection with business combination. For three months ended March 31, 2025
and for the year ended December 31, 2024, $324,511 and
$527,145 of
business combination related cost have been incurred which $255,513 and
$389,099 were
reimbursed by Qianzhi, respectively. This activity has been recorded net in accompanying financial statements.
Forward
Purchase Agreement
On
January 13, 2025, the Company entered into Prepaid Forward Purchase Agreement (the “FPA”) by and among the Company,
NewCo, and the funds, accounts and/other investment vehicles managed by Harraden Circle Investments, LLC signatory thereto
(collectively, the “Purchaser”). See Note 1 for details. The Company recorded $1,929,656
loss on issuance of FPA liability and FPA liability reported in the accompanying consolidated statements of operations and balance
sheets, respectively, on the initial recognition of 500,000
Prepaid Forward Purchase Shares.
From
January 13, 2025 through March 31, 2025, the Company recorded $367,317
changes in fair value of FPA liability reported in the accompanying consolidated statements of operations. As of March 31, 2025, the
Company has $1,562,339
outstanding balance under FPA liability reported in the accompanying consolidated balance sheets.
NOTE
6 — SHAREHOLDERS’ EQUITY
Preferred
Shares — The Company is authorized to issue 2,000,000 preferred shares with a par value of $0.0001 per share with such
designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors.
As of March 31, 2025 and December 31, 2024, there were no preferred shares issued or outstanding.
Ordinary
Shares — The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders
of ordinary shares are entitled to one vote for each share. On February 27, 2023, the Sponsors received of the Founder Shares
in exchange for $ paid for offering costs borne by the Sponsors, of which an aggregate of up to of such Founder Shares
were subject to forfeiture to the extent that the underwriters’ over-allotment was not exercised in full or in part, so that the
number of Founder Shares will equal 20% of the Company’s issued and outstanding ordinary shares after the IPO (excluding shares
underlying the Private Placement Units). No ordinary shares are subject to forfeiture since the over-allotment was fully exercised on
July 17, 2023. As of March 31, 2025 and December 31, 2024, there was 2,266,500 ordinary shares issued and outstanding (excluding 847,905
and 6,900,000 shares subject to possible redemption, respectively).
Rights
— Except in cases where the Company is not the surviving company in a business combination, each holder of a right will
automatically receive one-tenth (1/10) of one ordinary share upon consummation of the initial Business Combination. The Company will
not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole
share or otherwise addressed in accordance with the applicable provisions of Cayman law. In the event the Company is not the surviving
company upon completion of the initial Business Combination, each holder of a right will be required to affirmatively convert his, her
or its rights in order to receive the one-tenth (1/10) of one ordinary share underlying each right upon consummation of the business
combination. If the Company is unable to complete the initial Business Combination within the required time period and the Company will
redeem the public shares for the funds held in the trust account, holders of rights will not receive any of such funds for their rights
and the rights will expire worthless.
NOTE
7 — Fair Value Measurements
FAIR VALUE MEASUREMENTS
The
fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would
have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction
between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company
seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable
inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is
used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities:
|
Level
1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in
which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing
basis. |
|
|
|
Level
2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets
or liabilities and quoted prices for identical assets or liabilities in markets that are not active. |
|
|
|
Level
3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
The
following table presents information about the Company’s assets and liabilities
that are measured at fair value on a recurring basis at March 31, 2025 and December 31, 2024, and indicates the fair value hierarchy
of the valuation inputs the Company utilized to determine such fair value.
SCHEDULE
OF MEASURED FAIR VALUE ON RECURRING BASIS
Nature | |
Level | | |
March
31, 2025 | | |
December
31, 2024 | |
Assets: | |
| | | |
| | | |
| | |
Marketable
securities held in the trust account | |
| 1 | | |
$ | 9,372,109 | | |
$ | 75,794,241 | |
Cash
equivalents | |
| 1 | | |
$ | 29,806 | | |
$ | 103,774 | |
| |
| | | |
| | | |
| | |
Liabilities: | |
| | | |
| | | |
| | |
FPA liability | |
| 3 | | |
$ | 1,562,339 | | |
$ | - | |
FPA Liability
The
Company established the fair value of the FPA liability using Black Scholes Model that values based on future projections of the
various potential outcomes, and classified as a Level 3 fair value measurement.
The
following table provides additional quantitative information regarding the Level 3 fair value measurement inputs at their measurement
dates for the FPA liability:
SCHEDULE
OF INFORMATION REGARDING THE LEVEL 3 FAIR VALUE MEASUREMENT INPUTS AT THEIR MEASUREMENT DATES
| |
At
initial issuance
January 13, 2025 | | |
March
31, 2025 | |
Stock price | |
$ | 6.72 | | |
$ | 7.85 | |
Expected
redemption price | |
$ | 10.99 | | |
$ | 11.05 | |
Time
to expiration | |
| 1.46 | | |
| 1.25 | |
Risk-free
rate | |
| 4.3 | % | |
| 4.0 | % |
Volatility | |
| 35.0 | % | |
| 35.0 | % |
Dividend
yield | |
| 0.0 | % | |
| 0.0 | % |
The
following table presents the changes in the fair value of FPA liability for three months ended March 31, 2025:
SCHEDULE
OF FAIR VALUE OF FORWARD PURCHASE AGREEMENT LIABILITY
| |
| | |
January
1, 2025 | |
$ | - | |
Change
in fair value | |
| (367,317 | ) |
Fair
value of FPA liability as of March 31, 2025 | |
$ | 1,562,339 | |
Commitment Shares
50,000 Commitment Shares is measured at the grant
date, based on the estimated fair value of the award, and is recognized as an expense over the requisite service period. The fair
value of the financing expenses was measured based on the grant-date market price of $6.72 per share and classified as a Level 1 fair
value measurement. The resulting fair value totaled $336,000.
NOTE
8 — SUBSEQUENT EVENTS
The
Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements
were available to be issued. Based upon this review, the Company identified the following subsequent event that would have required
adjustment or disclosure in the financial statements.
On May 28, 2025, the Company received a written
notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) indicating
that the Company is not in compliance with Listing Rule 5250(c)(1) because the Company has failed to file its Quarterly Report on Form
10-Q for the quarter ended March 31, 2025 (the “Delinquent Report”). The Notice stated that no later than July 28, 2025,
the Company is required to submit a plan to regain compliance with respect to the filing of the Delinquent Report. If NASDAQ accepts
the Company’s plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the
Delinquent Report (or until November 17, 2025) to regain compliance. The Company is continuing to work diligently to complete the Delinquent
Report. If the Company is unable to file the Delinquent Report by July 28, 2025, it intends to file a plan to regain compliance with
NASDAQ. This notification has no immediate effect on the listing of the Company’s shares on NASDAQ. There can be no assurance,
however, that the Company will be able to regain compliance with the listing requirements discussed above or otherwise satisfy the other
NASDAQ listing criteria.
Item
2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations
References
to the “Company,” “our,” “us” or “we” refer to Bowen Acquisition Corp. The following
discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the
unaudited consolidated financial statements and the notes related thereto. Certain information contained in the discussion and
analysis set forth below includes forward-looking statements. Our actual results may differ materially from those anticipated in
these forward-looking statements as a result of many factors.
Overview
We
are a blank check company incorporated on February 17, 2023 as a Cayman Islands exempted company and incorporated for the purpose of
effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more
businesses. While we intend to focus our search on businesses in Asia, we are not limited to a particular industry or geographic region
for purposes of consummating an initial business combination. We intend to effectuate our initial business combination using cash from
the proceeds of this offering and the private placement of the private units, promissory loans with target or related parties, the proceeds
of the sale of our securities in connection with our initial business combination, our shares, debt or a combination of cash, stock and
debt.
We
expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete
a Business Combination will be successful.
Results
of Operations
We
have neither engaged in any operations nor generated any revenues to date. Our only activities since inception through March 31, 2025
were organizational activities, those necessary to prepare for the IPO described below, and since
the closing of the IPO, identifying a target company for our initial Business Combination, and professional costs related with the initial
Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination.
We generated non-operating income in the form of interest income on marketable securities held after the IPO. We expect that we will
incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance),
as well as for due diligence expenses in connection with searching for, and completing, a Business Combination.
For
the three months ended March 31, 2025, we had a net loss of $2,039,997, which consists of a loss of $134,736 derived from operating
costs, interest expense of $104,721, loss on issuance of FPA liability of $1,929,656, change in fair value of forward
purchase agreement of $367,317, and financing expense of $336,000, offset by income earned on the Trust Account
of $97,321 and bank interest income of $478.
For
the three months ended March 31, 2024, we had a net income of $786,362, which consists of a loss of $137,130 derived from formation and
operating costs offset by income earned on the Trust Account of $923,492.
Liquidity,
Capital Resources and Going Concern
On
July 14, 2023, we consummated our IPO of 6,000,000 Units, at $10.00 per Unit, generating gross proceeds of $60,000,000. Simultaneously
with the closing of our IPO, we consummated the sale of 330,000 Private Placement Units at a price of $10.00 per Private Placement Unit
in a private placement to the Sponsors, generating total gross proceeds of $3,300,000.
On
July 17, 2023, the underwriters exercised the over-allotment option in full to purchase 900,000 Units. As a result, on July 18, 2023,
we sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds of $9,000,000. Simultaneously with the closing of the
full exercise of the over-allotment option, we completed the private sale of an aggregate of 31,500 Private Placement Units, at a purchase
price of $10.00 per Private Placement Unit, generating gross proceeds of $315,000. Transaction costs amounted to $3,318,898 consisting
of $1,725,000 of cash underwriting fees and $1,593,898 of other offering costs.
Following
the closing of the IPO and the sale of over-allotment units, an amount of $69,690,000 ($10.10 per Unit) from the net proceeds of the
sale of the Units in the IPO and the Private Placement was placed in a trust account. The funds held in the Trust Account may be invested
in U.S. government securities with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a
money market fund selected by us. We intend to use substantially all of the funds held in the trust account, including any amounts representing
interest earned on the trust account, to complete our initial business combination. To the extent that our capital stock or debt is used,
in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the trust account
will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our
growth strategies.
As
of March 31, 2025, we had cash and cash equivalent of $29,806. We will use these funds primarily to complete the business combination.
This includes conducting ongoing due diligence, obtaining necessary regulatory and shareholder approvals, preparing required filings
and disclosures, structuring and negotiating transaction terms, and covering costs related to legal, financial, and other advisory services.
Additionally, funds may be used to pay taxes to the extent the interest earned on the trust account is not sufficient to pay our taxes.
In order to fund working capital deficiencies or finance transaction costs
in connection with an intended initial business combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and
directors may, but are not obligated to, loan us funds on a non-interest bearing basis as may be required. If we complete our initial
business combination, we would repay such loaned amounts. In the event that our initial business combination does not close, we may use
a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would
be used for such repayment. Other than as described above, the terms of such loans by our officers and directors, if any, have not been
determined and no written agreements exist with respect to such loans.
As
of March 31, 2025, we had cash and cash equivalent of $29,806 and a working capital deficit of
$2,600,374. We have incurred and expect to continue to incur significant professional costs to remain as a public traded company and to incur
transaction costs in pursuit of a Business Combination. In connection with our assessment of going concern considerations in accordance
with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to
Continue as a Going Concern,” we believe that these conditions raise substantial doubt about our ability to continue as a going
concern. In addition, if we are unable to complete a Business Combination within the Combination Period and such period is not extended,
there will be a liquidation and subsequent dissolution. As a result, we have determined that such additional condition also raises substantial
doubt about our ability to continue as a going concern. Management expects to obtain additional funds from related parties to provide
the additional working capital necessary to carry out its objective to consummate a business combination. The consolidated financial
statements do not include any adjustments that might result from the outcome of the uncertainty.
Off-Balance
Sheet Financing Arrangements
We
have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of March 31, 2025. We do not
participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable
interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered
into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other
entities, or purchased any non-financial assets.
Related
Party Transactions
Please
refer to Financial Statement Note 4- Related Parties.
Other
Contractual Obligations
We
do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities reflected on our balance
sheet.
Registration
Rights
The
holders of the Founder Shares, EBC founder shares, Private Placement Units have certain “piggy-back” registration rights
with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to
register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides
that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until
the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection
with the filing of any such registration statements.
Business
Combination Marketing Agreement
We
have engaged EBC as an advisor in connection with its Business Combination to assist in holding meetings with the Company stockholders
to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors
that are interested in purchasing its securities in connection with its initial Business Combination and assist with press releases and
public filings in connection with the Business Combination. The Company will pay EBC a service fee for such services upon the consummation
of its initial Business Combination in an amount equal to 3.5% of the gross proceeds of the IPO. In addition, the Company will pay EBC
a service fee in an amount equal to 1.0% of the total consideration payable in the initial Business Combination if it introduces the
Company to the target business with whom it completes an initial Business Combination and the amount will be payable in cash and is due
at the closing date of the initial Business Combination. As of the filing date, no such service has been provided by EBC.
Forward
Purchase Agreement
On January 13, 2025, we
entered into Prepaid Forward Purchase Agreement (the “FPA”) by and among the Company, NewCo, and the funds, accounts and/other
investment vehicles managed by Harraden Circle Investments, LLC. See Financial
Statement Note 1 for details. The Company recorded $1,929,656 loss on issuance of FPA liability
and FPA liability reported in the accompanying consolidated statements of operations and balance sheets, respectively, on the initial
recognition of 500,000 Prepaid Forward Purchase Shares.
Critical
Accounting Policies and Estimates
The
preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted
in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during
the periods reported. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that
the estimate of the effect of a condition, situation, or set of circumstances that existed as of the date of the financial statements,
and that management considered in formulating its estimate, could change in the near term due to one or more future confirming events.
Accordingly, actual results may differ from these estimates. Management does not believe that we have any critical accounting estimates;
however, we have identified the following critical accounting policy:
Net
Income (Loss) per Share
The
Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. In order to determine the net income
(loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss)
allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net
loss less interest income and unrealized gain or loss on investments in trust account less any dividends paid. We then allocated the
undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable
shares. Any remeasurement of the accretion to redemption value of the ordinary shares subject to possible redemption was considered to
be dividends paid to the public shareholders.
Fair Value of Financial Instruments
The forward purchase option in the FPA
of the Company meets the definition of an obligation to repurchase shares by transferring assets arrangement under ASC 480 and therefore
qualify as financial instruments under ASC 820 “Fair Value Measurement.” The Company’s FPA liability is considered
to be Level 3 financial instruments measured at fair value on a recurring basis. See Financial
Statement Note 7 for details. The fair value of the Company’s other assets and liabilities,
which qualify as financial instruments under ASC 820, approximates the carrying amounts represented in the balance sheet, primarily due
to their short-term nature.
Recent
Accounting Standards
Management
does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect
on our consolidated financial statements.
Item
3 – Quantitative and Qualitative Disclosures About Market Risk
We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this item.
Item
4 – Controls and Procedures
Evaluation
of Disclosure Controls and Procedures
Disclosure
controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our
reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in
the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated
to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
As
required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an
evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2025. Based
upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
(as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective due solely to the material weakness in our
internal control over financial reporting related to the Company’s lack of qualified SEC reporting professional. As a result,
we performed additional analysis as deemed necessary to ensure that our consolidated financial statements were prepared in
accordance with US GAAP. Accordingly, management believes that the consolidated financial statements included in this Form 10-Q
present fairly, in all material respects, our financial position, result of operations and cash flows for the periods presented.
Management intends to continue implement remediation steps to improve our disclosure controls and procedures and our internal
control over financial reporting. Specifically, we intend to expand and improve our review process for complex securities and
related accounting standards. We have improved this process by enhancing access to accounting literature, identification of
third-party professionals with whom to consult regarding complex accounting applications and consideration of additional staff with
the requisite experience and training to supplement existing accounting professionals.
Changes
in Internal Control over Financial Reporting
There
were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
Part
II - Other Information
Item
2 – Unregistered Sales of Equity Securities and Use of Proceeds
On
February 27, 2023, Bowen Holding LP acquired an aggregate of 1,725,000 ordinary shares for an aggregate purchase price of $25,000. Bowen
Holding LP thereafter transferred an aggregate of 1,155,750 ordinary shares to Createcharm Holdings Ltd, our other sponsor. The Company
also issued to EarlyBirdCapital, Inc. 180,000 ordinary shares for an aggregate purchase price of $2,520 on March 15, 2023. The issuance
of the foregoing securities was exempt pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”).
On
July 14, 2023, the Company consummated the Initial Public Offering of 6,000,000 Units. Each Unit consists of one Ordinary Share, par
value $0.0001 per share, of the Company and one Right, each Right entitling the holder thereof to receive one-tenth of one Ordinary Share
upon the completion of the Company’s initial business combination. The Units were sold at an offering price of $10.00 per Unit,
generating gross proceeds of $60,000,000. EarlyBirdCapital, Inc. acted as sole book-running manager of the Initial Public Offering and
Revere Securities acted as co-manager of the Initial Public Offering. The securities in the offering were registered under the Securities
Act on a registration statement on Form S-1 (No. 333-272076). The Securities and Exchange Commission declared the registration statement
effective on July 11, 2023.
Simultaneously
with the consummation of the Initial Public Offering, the Company consummated the Private Placement of 330,000 Private Placement Units
at a price of $10.00 per Private Placement Unit, generating total proceeds of $3,300,000. The Private Placement Units were purchased
by Createcharm Holdings Ltd and EarlyBirdCapital, Inc. The Private Placement Units are identical to the Units sold in the Initial Public
Offering. The purchasers of the Private Placement Units have agreed not to transfer, assign or sell any of the Private Placement Units
or underlying securities (except to certain transferees) until after the completion of the Company’s initial business combination.
The issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.
On
July 17, 2023, the underwriters exercised their over-allotment option in full to purchase an additional 900,000 Units. As a result, on
July 18, 2023, the Company sold an additional 900,000 Units at $10.00 per Unit, generating gross proceeds of $9,000,000. In connection
with this sale, Createcharm Holdings Ltd and EarlyBirdCapital, Inc. also purchased an additional 31,500 Private Placement Units from
the Company, generating gross proceeds of $315,000. The issuance of the additional Private Placement Units was made pursuant to the exemption
from registration contained in Section 4(a)(2) of the Securities Act.
As
of July 18, 2023, an aggregate of $69,690,000 has been deposited in the trust account established with Continental Stock Transfer &
Trust Company acting as trustee in connection with the Initial Public Offering ($10.10 per unit sold in the offering, including the over-allotment
option).
We
paid a total of $1,725,000 in underwriting discounts and commissions related to the Initial Public Offering.
For
a description of the use of the proceeds generated in the Initial Public Offering, see Part I, Item 2 of this Form 10-Q.
Item
5 – Other Information
During
the quarter ended March 31, 2025, no director or officer adopted or terminated any (i) “Rule 10b5-1 trading arrangement,”
as defined in Item 408(a) of Regulation S-K intending to satisfy the affirmative defense conditions of Rule 10b5–1(c) or (ii) “non-Rule
10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.
Item
6 – Exhibits
Exhibit
No. |
|
Description |
31.1* |
|
Certification
of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002. |
31.2* |
|
Certification
of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002. |
32.1** |
|
Certification
of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002. |
32.2** |
|
Certification
of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002. |
101.INS |
|
Inline
XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
the Inline XBRL document. |
101.SCH |
|
Inline
XBRL Taxonomy Extension Schema Document. |
101.CAL |
|
Inline
XBRL Taxonomy Extension Calculation Linkbase Document. |
101.DEF |
|
Inline
XBRL Taxonomy Extension Definition Linkbase Document. |
101.LAB |
|
Inline
XBRL Taxonomy Extension Label Linkbase Document. |
101.PRE |
|
Inline
XBRL Taxonomy Extension Presentation Linkbase Document. |
104 |
|
Cover
Page Interactive Data File. The cover page XBRL tags are embedded within the Inline XBRL document. |
*
Filed herewith
**
These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
BOWEN
ACQUISITION CORP |
|
|
|
Dated:
July 8, 2025 |
By. |
/s/
Jiangang Luo |
|
|
Jiangang
Luo |
|
|
Chief
Executive Officer
|
|
|
(Principal
Executive Officer) |
|
|
|
Dated:
July 8, 2025 |
By. |
/s/
Jing Lu |
|
|
Jing
Lu |
|
|
Chief
Financial Officer
|
|
|
(Principal
Financial and Accounting Officer) |